Barasertib (AZD1152-HQPA)

Catalog No.S1147 Synonyms: INH 34

Barasertib (AZD1152-HQPA) Chemical Structure

Molecular Weight(MW): 507.56

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • Targeting PI3K, a common downstream effector of RTKs, with a selective inhibitor (GDC0941) sensitizes SOX10 knockdown cells to vemurafenib. shRNAs targeting SOX10 were introduced into A375 cells by lentiviral transduction. pLKO.1 empty vector served as a control vector (Ctrl). Cells were seeded in 6-well plates at the same density in the presence or absence of drug(s) at the indicated concentration. Cells were cultured for 2 weeks in the absence of vemurafenib or 4 weeks in the presence of vemurafenib before fixing and staining.

    Nature 2014 508(7494), 118-22. Barasertib (AZD1152-HQPA) purchased from Selleck.

    Primary MKPs were treated with the Aurora B inhibitor AZD-1152, and then stimulated with 20 ng/ml TPO for 5 d. Cell morphology was analyzed by Giemsa staining (Bar, 20 祄; red arrows denote mature MKs; n = 6).

    J Exp Med 2014 10.1084/jem.20141123. Barasertib (AZD1152-HQPA) purchased from Selleck.

  • The alamarBlue assay revealed that AURKB inhibition with AZD1152 was effective in NB TICs at EC50 of 1.5 to 4.6 μmol/L, whereas AURKB inhibition was effective in SKPs at 12.4 μmol/L.

    Clin Cancer Res 2010 16, 4572-4582. Barasertib (AZD1152-HQPA) purchased from Selleck.

    : Barasertib inhibits AURKB specifically and triggers mitotic slippage. (a) Barasertib inhibits AURKB without affecting AURKA. Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Barasertib for 2 h. Nocodazole and MG132 were included to prevent mitotic exit. Lysates were prepared and analyzed with immunoblotting. Uniform loading was confirmed by immunoblotting for actin. (b) Barasertib induces mitotic slippage. HeLa cells expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Barasertib. Individual cells were then tracked for 24 h with time- lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). The key is the same as in Figure 1b. (c) Summary of Barasertib-mediated mitotic slippage. Live-cell imaging after Barasertib treatment was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period were quantified. (d) Genome reduplication after Barasertib-mediated mitotic slippage. HeLa cells were treated with the indicated concentrations of Barasertib for 36 h. DNA contents were analyzed with flow cytometry. (e) Barasertib induces mitotic slippage and genome reduplication in HCT116. Cells were treated with the indicated concentrations of Barasertib for 24 h. DNA contents were analyzed with flow cytometry. (f) Cytotoxicity induced by Barasertib. HeLa and HCT116 cells were cultured in the presence of the indicated concentrations of Barasertib for 48 h. Proliferation was assayed with WST-1 assay. (g) Barasertib induces genome reduplication and apoptosis. HeLa cells were incubated with 50 n M of Barasertib either in the presence or absence of the caspase inhibitor Z-VAD(OMe)-FMK. The cells were harvested at the indicated time points and analyzed with flow cytometry.

    Oncogene 2014 33, 3550-60. Barasertib (AZD1152-HQPA) purchased from Selleck.

  •  

    Dual inhibition of Aurora and SRC kinases specifically eliminates hyperploid cells. Experiment shown is same as a, b, but performed following treatment of OVCAR10 cells with MLN8237 (targeting AURKA) or AZD1152 (targeting AURKB);

    Oncogene 2012 31, 1217–1227. Barasertib (AZD1152-HQPA) purchased from Selleck.

    p53 phosphorylation by Aurora B. A, p53 reporter construct was co-transfected with the indicated plasmids into H1299 cells and reporter activation was determined as described under "Experimental Procedures". B, U2OS cells and H1299 cells were treated with AZD1152 (AZD) for 12 h at the indicated doses. Cell lysates were harvested and immunoblotted with Bax and actin antibodies. C, U2OS cells were treated with 100 ng/ml nocodazole (noc) overnight, and then shake off cells were harvested, washed with PBS, and reseeded. Approximately 2 h later, cells were either lysated or treated with dimethyl sulfoxide (DMSO) or AZD1152 for another 16 h before harvesting. Cell lysates were immunoblotted with Bax, phospho-H3, and actin antibodies. D, GST-p53 or GST control proteins were incubated with Aurora B protein and analyzed for phosphate incorporation (left panel). Coomassie staining of GSTp53 and GST protein is also shown (right panel). E, In vitro phosphorylation sites of GST-p53 identified by mass spectrometry analysis. F, GST-p53 wild-type and 3A mutant proteins were analyzed in a kinase assay as in B. G, plasmids encoding wild-type or 3A mutant (CMV)-FLAG-p53 were transiently transfected into H1299 cells, with or without Myc-Aurora B (AurB) expression vector. 20 h post-transfection, cells were lysed and subjected to immunoprecipitation (IP) with p53 antibody (fl-393). Precipitates were immunoblotted with antibodies to p53 (DO-1), Thr(P) and Ser(P), as indicated. Vec, vector.

     

     

    J Biol Chem 2011 286, 2236-44. Barasertib (AZD1152-HQPA) purchased from Selleck.

  • Fig. 5.A, inhibition of VEGF-mediated uterine edema. Compounds were administered intravenously at the indicated dose 30 min before estradiol challenge. Uterine edema was assessed 2 h thereafter. Inhibition > 35% of the response was significantly different from vehicle-treated group (P < 0.05). ED50(milligrams per kilogram) is shown within parentheses. Values are expressed as mean  S.E.M., n= 6 per group. IV, intravenously. B, induction of plasma PLGF after treatment with ABT-348. Mice-bearing tumors derived from a human NSCLC cell line (HCC827ER) were treated with 25 mg/kg ABT-348 via subcutaneous osmotic minipump. At the indicated time, plasma samples were obtained and assayed for murine PLGF. Values shown are the mean  S.E. (n = 5 per group). C, representative longitudinal MRI images showing gadolinium contrast enhancement in a rat glioma model with treatment with vehicle, ABT-348 (6.25 mg/kg i.p. b.i.d., every 7 days; two treatment cycles on days 11 and 18 after inoculation), or AZD1152(25 mg/kg i.v., every 4 days; two treatment cycles commencing on days 11 and 18 after inoculation). b, normal brain; t, tumor, Tx1, first treatment cycl e; Tx2, second treatment cycle. D,K transas a function of treatment cycle. Values represent the mean  S.E.M., n =12 per group.**, P < 0.01 vs. vehicle.

    J Pharmacol Exp Ther 2012 343(3), 617-27. Barasertib (AZD1152-HQPA) purchased from Selleck.

    1205Lu cells were treated for 48hours with the indicated concentrations of  AZD1152-HQPA. 

     

     

    Dr. Gao Zhang of University of Pennsylvania. Barasertib (AZD1152-HQPA) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Targets
Aurora B [1]
(Cell-free assay)
Aurora A [1]
(Cell-free assay)
0.37 nM 1368 nM
In vitro

AZD1152 displays >3000-fold selectivity for Aurora B as compared with Aurora A which has an IC50 of 1.368 μM. AZD1152 has even less activity against 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and Abl. AZD1152 inhibits the proliferation of hematopoietic malignant cells such as HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and K562 cells with IC50 of 3-40 nM, displaying ~100-fold potency than another Aurora kinase inhibitor ZM334739 which has IC50 of 3-30 μM. AZD1152 inhibits the clonogenic growth of MOLM13 and MV4-11 cells with IC50 of 1 nM and 2.8 nM, respectively, as well as the freshly isolated imatinib-resistant leukemia cells with IC50 values of 1-3 nM, more significantly compared with bone marrow mononuclear cells with IC50 values of >10 nM. AZD1152 induces accumulation of cells with 4N/8N DNA content, followed by apoptosis in a dose- and time-dependent manner. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTUXJoxNTVyMDDuUS=> NIDiSHI1QMLiaB?= MX3JR|UxRTJ3IH7N NE\GTYczPTJ5N{[1PS=>
LNCaP MoLoRZBweHSxc3nzJGF{e2G7 MV6wMVUxOCCwTR?= NGPCSWY1QMLiaB?= M{TDdIlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIghfGi{b4XnbEBk[XOyYYPlMVMhfXC{ZXf1cIF1cW:w MnLYNlUzPzd4NUm=
LNCaP MWHGeY5kfGmxbjDBd5NigQ>? M3rDN|UxKG6P M3\PUlQ5KGh? NGPBZYFqdmS3Y3XzJI1q[3KxboXjcIVqKHerdHigZY5mfWenbnnjJI1m[2ijbnnzcS=> MnHJNlUzPzd4NUm=
Ramos MlG1SpVv[3Srb36gRZN{[Xl? NUS2VGpbPTByIH7N NWTLdGZlOC15MjDo NWfwXHpncW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl NHPuT5kzOTN5MUS0Oi=>
Daudi  NILYOXRHfW6ldHnvckBCe3OjeR?= NFjV[5M2ODBibl2= MX6wMVczKGh? M4TIbYlvcGmkaYTzJGF2em:{YTDCJItqdmG|ZR?= MUCyNVM4OTR2Nh?=
L540 Mk\FSpVv[3Srb36gRZN{[Xl? Mnu1OVAxKG6P MXiwMVczKGh? NHjXfIRqdmirYnn0d{BCfXKxcnGgRkBscW6jc3W= NGrPNpkzOTN5MUS0Oi=>
BJAJ MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTHXYl4PTByIH7N NHqwXXoxNTd{IHi= MXvpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MkLUNlE{PzF2NE[=
Ramos NX7jTmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnrOVAxKG6P NGD6cnMxNTd{IHi= MX7pcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MWSyNVM4OTR2Nh?=
Raji MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KydlUxOCCwTR?= M2HnN|AuPzJiaB?= NHy5VotqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NXu1OYN5OjF|N{G0OFY>
Daudi  M4PMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TGWlUxOCCwTR?= NUexSGVvOC15MjDo NG\LdpdqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MnjsNlE{PzF2NE[=
L428 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XmZVUxOCCwTR?= MoPSNE04OiCq NXfEWodRcW6qaXLpeJMh[2WubDDndo94fGh? M3fqTlIyOzdzNES2
KM-H2 NFO4b5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OzWlUxOCCwTR?= MoLkNE04OiCq NFHuXopqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MnfvNlE{PzF2NE[=
HDLM-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rjOVUxOCCwTR?= M4\rRlAuPzJiaB?= NVzxZVNjcW6qaXLpeJMh[2WubDDndo94fGh? NF\ZW3UzOTN5MUS0Oi=>
L450 M3;tWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXjNZh{PTByIH7N M4fMOVAuPzJiaB?= NYrzToYycW6qaXLpeJMh[2WubDDndo94fGh? M{XWXVIyOzdzNES2
BJAJ NGXMdG5CeG:ydH;zbZMhSXO|YYm= MXG1NFAhdk1? MVSwMVczKGh? MYrpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NWXW[GQ2OjF|N{G0OFY>
Ramos M1H3S2Fxd3C2b4Ppd{BCe3OjeR?= NUnVVmt4PTByIH7N NV3CWWU{OC15MjDo NEe1RWtqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NIjQbmwzOTN5MUS0Oi=>
Raji NWHOcmZvSXCxcITvd4l{KEG|c3H5 MVS1NFAhdk1? NEe0VI8xNTd{IHi= MlPWbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MoDENlE{PzF2NE[=
Daudi  NVfjUmI{SXCxcITvd4l{KEG|c3H5 M2[1NFUxOCCwTR?= MVSwMVczKGh? NWD6SXV[cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MXyyNVM4OTR2Nh?=
L428 MXTBdI9xfG:|aYOgRZN{[Xl? Mo\NOVAxKG6P M37pOlAuPzJiaB?= M4nweIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NFe0XXMzOTN5MUS0Oi=>
KM-H2 NY\LSZN7SXCxcITvd4l{KEG|c3H5 NGj4fJA2ODBibl2= NYC4S4l[OC15MjDo MnmxbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NYLUbHpUOjF|N{G0OFY>
HDLM-2 MUTBdI9xfG:|aYOgRZN{[Xl? M2PidFUxOCCwTR?= MV6wMVczKGh? Mkn6bY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MoHhNlE{PzF2NE[=
L450 Ml\WRZBweHSxc3nzJGF{e2G7 MnzqOVAxKG6P NF;ve4QxNTd{IHi= MnTibY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NEm4eXgzOTN5MUS0Oi=>
SW620 M3vyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\Yd2lGSzVyPUGwxtEzNjFibl2= NUDsSY1TOjF{NEWwPVA>
HCT116 NF\pcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\FR|UxRTFzwsGzMlMhdk1? NGXXToIzOTJ2NUC5NC=>
MDA-MB-435 M2\qUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvPZYoxOC1zMECwNEBvVQ>? MVuyMVUh\A>? NULBZpJnTE2VTx?= MnPITWM2OD1zMkWgcm0> MoLwNlAyPzV7Mk[=
MDA-MB-468 NGf4cplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMVExODByIH7N MXGyMVUh\A>? NYTsXZdXTE2VTx?= MXHJR|UxRTF2IH7N M{fJTlIxOTd3OUK2
MDA-MB-231 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7VRnloOC1zMECwNEBvVQ>? M4m2SVIuPSCm M4HNOGROW09? NVHzTZZDUUN3ME2xNFUhdk1? MX[yNFE4PTl{Nh?=
BT474 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPSfJQxNTFyMECwJI5O NYfPcI4{Oi13IHS= NXXnW49ITE2VTx?= NVvKdlRGUUN3ME24JI5O M1vLd|IxOTd3OUK2
MDA-MB-361 M3HvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nNTlAuOTByMECgcm0> NVfISmF[Oi13IHS= MoWySG1UVw>? NGLLXFlKSzVyPUewJI5O MnjCNlAyPzV7Mk[=
HER18 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:wMVExODByIH7N MlrZNk02KGR? NGDjV3dFVVOR NEXOOFFKSzVyPUKwJI5O Mnv5NlAyPzV7Mk[=
HER18 NHHRWXdCeG:ydH;zbZMhSXO|YYm= M{Hic|ExOCCwTR?= NFS0WJoxNzJ2L{S4JIg> NUDTd2VPTE2VTx?= M4TxfYlv\HWlZYOgZZBweHSxc3nzJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNicH;0[Y51cWGu MnjyNlAyPzV7Mk[=
MDA-MB-231 Mmn0RZBweHSxc3nzJGF{e2G7 NXHGW2ZMOTB3IH7N MY[wM|I1NzR6IHi= M33idWROW09? MVLpcoR2[2W|IHHwc5B1d3OrczDhcoQhemWmdXPld{BkdG:wb3flcolkKHCxdHXueIlidA>? MnK2NlAyPzV7Mk[=
JHH-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\z[|AvO+LCk{GwNFDDqG6P NHnKb2c4OiCq M1rvXGVEPTB;MUeuOOKyOS5yIH7N M{XJeVE6QTF|OUO1
JHH-2 M4LxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXYXFJDOC5|4pETNVAxOMLibl2= M{L4dVczKGh? NG\ESZFGSzVyPUKxPE4xyrFzMD64JI5O NYTBeJpJOTl7MUO5N|U>
JHH-4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHnSFY3OC5|4pETNVAxOMLibl2= NHzpXZM4OiCq M1XBPGVEPTB;MUW1MlbDuTF4Lkigcm0> MoG1NVk6OTN7M{W=
HuH-1 NUHQfJZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGwd24xNjQkgKOxNFAxyqCwTR?= MoHFO|IhcA>? Mke3SWM2OD1{Nz6zxtE2NjBibl2= NX;CS4ZYOTl7MUO5N|U>
HuH-6 NVG1R3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nCeVAvO+LCk{GwNFDDqG6P MkHMO|IhcA>? M2LNc2VEPTB;Mz63xtExNjZibl2= NGXjSGEyQTlzM{mzOS=>
HuH-7 NGXpVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK3dWdSOC5|4pETNVAxOMLibl2= M4TRUFczKGh? NEK0[ZVGSzVyPU[uPOKyOC5|IH7N NEXRdIQyQTlzM{mzOS=>
HLE M37XW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTZe2UxNjQkgKOxNFAxyqCwTR?= NFruV|U4OiCq NUDiNIhETUN3ME20OU46yrF4LkSgcm0> MYWxPVkyOzl|NR?=
HLF MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL2NE4{6oDVMUCwNOKhdk1? M13xZlczKGh? M1rKOGVEPTB;MUK2MlHDuTF{LkKgcm0> MoKzNVk6OTN7M{W=
PLC/PRF/5 NVvXZ4YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi4UFlROC5|4pETNVAxOMLibl2= MlnXO|IhcA>? M2DMdWVEPTB;N{[uPeKyQS57IH7N Mle4NVk6OTN7M{W=
SK-Hep1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6wMlPjiJNzMECwxsBvVQ>? MUm3NkBp MnfTSWM2OD1{MT65xtEyNjJibl2= M{Wyb|E6QTF|OUO1
Hep3B M4PCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TuN|AvO+LCk{GwNFDDqG6P MUO3NkBp M4HBW2VEPTB;Nz62xtEyNjJibl2= NH65N2MyQTlzM{mzOS=>
HepG2 NHK4N4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C1ZlAvO+LCk{GwNFDDqG6P MWe3NkBp MkmySWM2OD1zND63xtEyNjdibl2= NEK1cIUyQTlzM{mzOS=>
Ramos MXTBdI9xfG:|aYOgRZN{[Xl? NFeydmczPS93MD:xNFAhdk1? NFnvfIU1QCCq NYe1S5lrcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKGOuZXH2[YQh\m:{bYOgc4YhWEGUUDDhcoQh[2G|cHHz[UA{ M2LqNVE6QDJ|MU[4
Daudi  NYDmN5poSXCxcITvd4l{KEG|c3H5 MW[yOU82OC9zMECgcm0> NFPTXWQ1QCCq NEOxeG9qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> M2DifFE6QDJ|MU[4
BALM-14 MVfBdI9xfG:|aYOgRZN{[Xl? MlW3NVIvPS9{NT:1NEBvVQ>? MWm0PEBp NHqyXHhqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> NIH2XYQyQTh{M{G2PC=>
BALM-27 M1TK[2Fxd3C2b4Ppd{BCe3OjeR?= MlXYNVIvPS9{NT:1NEBvVQ>? M1HLOVQ5KGh? MXzpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= MVKxPVgzOzF4OB?=
NB4 NE\RcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm4NE4xOS9yLkGvNUDPxE1? NHW1NVE1QCCq Mly4bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= MoTkNVg{Pjd2OES=

... Click to View More Cell Line Experimental Data

In vivo Administration of AZD1152 (25 mg/kg) alone markedly suppresses the growth of MOLM13 xenografts, confirmed by the observation of necrotic tissue with infiltration of phagocytic cells. [1] In addition, AZD1152 (10-150 mg/kg/day) significantly inhibits the growth of a variety of human solid tumor xenografts, including colon, breast, and lung cancers, in a dose-dependent manner. [2]

Protocol

Cell Research
+ Expand
  • Cell lines: HL-60, NB4, MOLM13, PALL-2, MV4-11, EOL-1, and K562 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 24 or 48 hours
  • Method: Cells are exposed to various concentrations of AZD1152 for 24 or 48 hours. Cell proliferation is measured by 3H-thymidine uptake (isotope added 6 hours before harvest), and the concentration that induced 50% growth inhibition (IC50) is calculated from dose-response curves. Cell cycle analysis is performed by flow cytometry. Cell apoptosis is measured by annexin V–FITC apoptosis detection kit.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Female immune-deficient BALB/c nude mice subcutaneously injected with MOLM13 cells
  • Formulation: Dissolved in 3M Tris, pH 9.0, at a concentration of 2.5 mg/mL
  • Dosages: 5 or 25 mg/kg
  • Administration: Intraperitoneal injection 4 times a week or every another day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.96 mM)
Ethanol 3 mg/mL (5.91 mM)
Water <1 mg/mL
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.56
Formula

C26H30FN7O3

CAS No. 722544-51-6
Storage powder
in solvent
Synonyms INH 34

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

  • Answer:

    S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) supplier | purchase Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) cost | Barasertib (AZD1152-HQPA) manufacturer | order Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID